GlassScriptPhysician profile
Gregory Keith Brock
NPI 1952374779
$437.03
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $41.36 · 2021: $151 · 2022: $12.44.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $161.89 | 2019-2021 | |
| Grifols USA, LLC | $90.37 | 2019-2021 | |
| Pfizer INC. | $42.98 | 2020-2021 | |
| Covis Pharma Gmbh | $25.92 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.58 | 2021 | |
| Gilead Sciences, INC. | $19.55 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.16 | 2019 | |
| Exeltis, USA INC. | $12.83 | 2021 | |
| Dexcom, INC. | $12.44 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.06 | 2019 | |
| Acclarent, INC | $11.14 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.11 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Brock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.